Latest News

Results of a study performed at the University of Pittsburgh Medical Center (UPMC) reports that high concentrations of specific proteins in the blood of patients with idiopathic pulmonary fibrosis (IPF) that also met specific clinical parameters predicted poor overall survival.

NIH stops one treatment arm of trial; other two treatments to continue

Study points to a phosphorylation pathway that may contribute to the development of lung injury and fibrosis

By Dr. Daniel Dilling, FCCP

Lung transplantation, at one time, seemed like science fiction, but innovations in surgical technique and immunosuppression made it clinical reality. Limited supply of donor lungs and the vagaries of immunosuppression still limit its success.

Oyster Bay, N.Y. – Dr. Yang Zhou, associate research scientist working in Dr. Jack Elias’s lab at the Yale University School of Medicine, has been awarded a grant to investigate potential biomarkers and therapeutic targets of pulmonary fibrosis.

By Charles Bankhead, Staff Writer, MedPage Today
Published: September 22, 2011
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

Launches in other European countries to follow in 2012

Conference call and webcast scheduled today at 8:30 a.m. EDT

Actelion Pharmaceuticals Ltd / Actelion reports results of exploratory study with macitentan in IPF patients - promising long-term safety and tolerability profile - efficacy data not supportive of Phase III in IPF . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

WASHINGTON (AP) — A lawsuit that had threatened to end the Obama administration's funding of embryonic stem cell research was dismissed Wednesday, allowing the U.S. to continue supporting a search for cures to deadly diseases over protests that the work relies on destroyed human embryos.

BRISBANE, CA, July 7, 2011 - InterMune announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF).